Showing 1 - 20 of 23 Items
Showing 1 - 20 of 23 Items
Sort By: Relevance
Journal Article
|Research
2025-04-09 • Antimicrobial Agents and Chemotherapy
2025-04-09 • Antimicrobial Agents and Chemotherapy
Risk factors for baseline bedaquiline (BDQ) resistance, amplification during treatment, and correlations with treatment outcomes are not fully understood. This cohort included Armenia...
Journal Article
|Research
2023-01-01 • International Journal of Tuberculosis and Lung Disease
2023-01-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND
The WHO provides standardized outcome definitions for rifampicin-resistant (RR) and multidrug-resistant (MDR) TB. However, operationalizing these definitions can be challe...
The WHO provides standardized outcome definitions for rifampicin-resistant (RR) and multidrug-resistant (MDR) TB. However, operationalizing these definitions can be challe...
Journal Article
|Letter
2015-02-01 • American Journal of Respiratory and Critical Care Medicine
2015-02-01 • American Journal of Respiratory and Critical Care Medicine
Journal Article
|Short Report
2019-11-02 • Clinical Infectious Diseases
2019-11-02 • Clinical Infectious Diseases
Delamanid should be effective against highly resistant strains of Mycobacterium tuberculosis, but uptake has been slow globally. In the endTB (expand new drug markets for TB) Observation...
Journal Article
|Research
2022-06-21 • Public Health Action
2022-06-21 • Public Health Action
BACKGROUND
Direct-acting antivirals (DAAs) are not widely used for patients with chronic hepatitis C virus (HCV) infection and multidrug- or rifampicin-resistant TB (MDR/RR-TB). We d...
Direct-acting antivirals (DAAs) are not widely used for patients with chronic hepatitis C virus (HCV) infection and multidrug- or rifampicin-resistant TB (MDR/RR-TB). We d...
Journal Article
|Research
2014-02-01 • International Journal of Tuberculosis and Lung Disease
2014-02-01 • International Journal of Tuberculosis and Lung Disease
SETTING
Armenia, a country with a high prevalence of drug-resistant tuberculosis (DR-TB).
OBJECTIVE
To identify factors related to default from DR-TB treatment in Yereva...
Armenia, a country with a high prevalence of drug-resistant tuberculosis (DR-TB).
OBJECTIVE
To identify factors related to default from DR-TB treatment in Yereva...
Journal Article
|Research
2014-10-13 • Journal of Infectious Diseases
2014-10-13 • Journal of Infectious Diseases
The success of the current treatment regimen for multidrug-resistant tuberculosis (MDR-TB) is poor partly due to a high defaulter rate. Many studies explored predictors of poor outcomes,...
Journal Article
|Research
2018-03-08 • PLOS One
2018-03-08 • PLOS One
The emergence of resistance to anti-tuberculosis (DR-TB) drugs and the HIV epidemic represent a serious threat for reducing the global burden of TB. Although data on HIV-negative DR-TB t...
Journal Article
|Research
2018-12-06 • Archives of Disease in Childhood
2018-12-06 • Archives of Disease in Childhood
OBJECTIVE
We aimed to measure the prevalence and incidence of latent tuberculosis infection (LTBI) and tuberculosis (TB) disease in children in close contact with patients with drug-...
We aimed to measure the prevalence and incidence of latent tuberculosis infection (LTBI) and tuberculosis (TB) disease in children in close contact with patients with drug-...
Journal Article
|Research
2018-02-13 • Lancet Infectious Diseases
2018-02-13 • Lancet Infectious Diseases
BACKGROUND
Bedaquiline and delamanid have been approved for treatment of multidrug-resistant (MDR) tuberculosis in the past 5 years. Because of theoretical safety concerns, patients ...
Bedaquiline and delamanid have been approved for treatment of multidrug-resistant (MDR) tuberculosis in the past 5 years. Because of theoretical safety concerns, patients ...
Protocol
|Research Protocol
2019-08-20 • BMC Infectious Diseases
2019-08-20 • BMC Infectious Diseases
BACKGROUND
At a time when programs were struggling to design effective regimens for the treatment of multidrug-resistant tuberculosis (MDR-TB), the marketing authorization of bedaqui...
At a time when programs were struggling to design effective regimens for the treatment of multidrug-resistant tuberculosis (MDR-TB), the marketing authorization of bedaqui...
Journal Article
|Research
2014-10-21 • Public Health Action
2014-10-21 • Public Health Action
We assessed the performance of decentralised tuberculosis (TB) out-patient centres in tuberculosis (TB) case notification and treatment success in Armenia. An average threshold case noti...
Journal Article
|Research
2019-05-01 • Emerging Infectious Diseases
2019-05-01 • Emerging Infectious Diseases
Bedaquiline is recommended by the World Health Organization for the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB). We pooled data from 5 c...
Journal Article
|Research
2015-06-01 • Educ Ther Patient/Ther Patient Educ
2015-06-01 • Educ Ther Patient/Ther Patient Educ
INTRODUCTION
As part of a programme providing care for patients with drug-resistant tuberculosis (DR-TB) in Armenia, participation in therapeutic patient education (TPE) is proposed ...
As part of a programme providing care for patients with drug-resistant tuberculosis (DR-TB) in Armenia, participation in therapeutic patient education (TPE) is proposed ...
Journal Article
|Research
2019-09-21 • Public Health Action
2019-09-21 • Public Health Action
The World Health Organization (WHO) currently recommends Xpert® MTB/RIF as the initial test for all people with presumptive tuberculosis (TB). A number of challenges have been reported, ...
Journal Article
|Letter
2019-05-01 • Lancet Infectious Diseases
2019-05-01 • Lancet Infectious Diseases
Here we report on the final outcomes for the cohort of 28 patients from Armenia, India, and South Africa who initiated regimens containing the combination of bedaquiline and delamanid fr...
Journal Article
|Research
2019-10-01 • International Journal of Tuberculosis and Lung Disease
2019-10-01 • International Journal of Tuberculosis and Lung Disease
INTRODUCTION
Identification of good prognostic marker for tuberculosis (TB) treatment response is a necessary step on the path towards a surrogate marker to reduce TB trial duration....
Identification of good prognostic marker for tuberculosis (TB) treatment response is a necessary step on the path towards a surrogate marker to reduce TB trial duration....
Journal Article
|Research
2016-02-01 • International Journal of Tuberculosis and Lung Disease
2016-02-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND
The World Health Organization recommends adding bedaquiline or delamanid to multidrug-resistant tuberculosis (MDR-TB) regimens for which four effective drugs are not avail...
The World Health Organization recommends adding bedaquiline or delamanid to multidrug-resistant tuberculosis (MDR-TB) regimens for which four effective drugs are not avail...
Journal Article
|Research
2018-07-01 • International Journal of Tuberculosis and Lung Disease
2018-07-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND AND SETTING
Bedaquiline (BDQ) was initially only available through compassionate use programmes.
OBJECTIVE
To assess the effectiveness and safety of multidrug...
Bedaquiline (BDQ) was initially only available through compassionate use programmes.
OBJECTIVE
To assess the effectiveness and safety of multidrug...
Journal Article
|Research
2016-01-01 • Public Health Panorama
2016-01-01 • Public Health Panorama
BACKGROUND AND OBJECTIVE
Adherence to treatment is an important factor for the successful treatment of tuberculosis (TB). Many countries have introduced incentive mechanisms to enhan...
Adherence to treatment is an important factor for the successful treatment of tuberculosis (TB). Many countries have introduced incentive mechanisms to enhan...